The Times has an article today regarding a trial in London. I remember there was a post here - ? April - saying it was one of the many drugs being looked at, but I certainly hadn't seen anything else since. I imagine those of us who are on it will wonder whether that might already be a benefit to us if we were unlucky enough to get seriously ill, but I imagine that answer is a long way down the line.
This is the first bit of a longer article:
"Patients with coronavirus will be treated with a drug used to fight rare blood cancers in a trial beginning next week.
Scientists want to see whether Ruxolitinib can reduce complications in deteriorating Covid-19 patients. They believe it could reduce the need for treatment in intensive care and in some cases save lives.
Patients with severe Covid-19 can experience hyperinflammation, which can send the body into shock and damages organs. Ruxolitinib is a “JAK inhibitor”, which blocks the signal required to produce more pro-inflammatory cytokines and therefore reduce inflammatory activity.
The trial led by King’s College London involves 19 patients based at Guy’s and St Thomas’ hospitals in London. If the first phase is successful another 59 patients will be enrolled.
The drug is approved for use in certain myeloproliferative neoplasms — rare forms of blood cancer — and is the most common medication for these conditions." and it continues further.
Impact of COVID-19 infection in blood cancer patients
Encouraging Update Ruxolitinib PV Trial Phase 3
Covid-19 
Ruxolitinib and skin cancers
Ruxolitinib For 5 Months Now With PV
